Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of fluorofenedione in preparing drug for treating acute kidney injury

A kind of acute kidney injury, flufenidone technology, applied in the field of medicine

Inactive Publication Date: 2018-07-17
CENT SOUTH UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Currently there is no specific treatment drug or measure to reverse AKI

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of fluorofenedione in preparing drug for treating acute kidney injury
  • Application of fluorofenedione in preparing drug for treating acute kidney injury
  • Application of fluorofenedione in preparing drug for treating acute kidney injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment 1: observe the curative effect of flufenidone treatment cisplatin-induced acute kidney injury in rats

[0022] 1. Experimental method

[0023] To prepare an experimental animal model of cisplatin-induced acute kidney injury, and to observe the curative effect of flufenidone on acute kidney injury.

[0024] Clean grade Sprague-Dawley rats (7-8 weeks old, male, body weight 180g-200g), 18 in total, were randomly divided into 3 groups: normal group, model group, flufenidone group (500mg / kg.d) , 6 rats in each group, began administration 3 days before modeling (D1), and began to give model group and flufenidone treatment group intraperitoneal injection of cisplatin solution (8mg / kg, with sterile saline before injection) on D3. The dilution concentration was 1 mg / mL), and the normal group was injected intraperitoneally with an equal volume of normal saline. On the sixth day (D9) after modeling, 24-hour urine was collected from the rats through metabolic cages, an...

Embodiment 2

[0058] Example 2: Observing the curative effect of flufenidone on acute kidney injury in mice induced by ischemia-reperfusion

[0059] 1. Experimental method

[0060] Prepare an experimental animal model of acute kidney injury induced by ischemia-reperfusion, and observe the curative effect of flufenidone on acute kidney injury.

[0061] Clean grade C57 mice (7-8 weeks old, male, body weight 180g-200g), a total of 17, were randomly divided into 3 groups: normal group, model group, flufenidone group (500mg / kg.d), in which There were 5 rats in the normal group, 5 rats in the model group, and 7 rats in the flufenidone treatment group. Administration was started 3 days before modeling (D1), and modeling was started on D3. The specific steps are as follows: After anesthetizing the mouse with chloral hydrate solution, prepare the skin, place the mouse on a thermostat, and set the temperature at 36.7°C. The tissues above the bilateral kidney area were cut layer by layer along the ...

Embodiment 3

[0073] Example 3: Observing the curative effect of small doses of flufenidone (250mg / kg.d) in the treatment of acute kidney injury in mice induced by ischemia-reperfusion

[0074] 1. Experimental method

[0075] Prepare an experimental animal model of ischemia-reperfusion-induced acute kidney injury, and observe the curative effect of small doses of flufenidone on acute kidney injury.

[0076] Clean grade C57 mice (7-8 weeks old, male, body weight 180g-200g), a total of 17, were randomly divided into 3 groups: normal group, model group, flufenidone group (250mg / kg.d), in which There were 5 rats in the normal group, 7 rats in the model group, and 4 rats in the flufenidone treatment group. Administration was started 3 days before modeling (D1), and modeling was started on D3. The specific steps are as follows: After anesthetizing the mouse with chloral hydrate solution, prepare the skin, place the mouse on a thermostat, and set the temperature at 36.7°C. The tissues above the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses novel application of fluorofenedione in preparing a drug for treating acute kidney injury.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of flufenidone in the preparation of medicines for treating acute kidney injury. Background technique [0002] Acute kidney injury (Acute kidney injury, AKI) is a group of clinical syndromes, which refers to a sudden decline in renal function in a short period of time, manifested as azotemia, water electrolyte and acid-base balance, and systemic symptoms, which may be accompanied by rare Urine or no urine. AKI is a common critical disease in clinical practice. Its etiology is complicated, it is often combined with damage to other organs at the same time, and the mortality rate is extremely high, which brings great challenges to clinical work. About 13 million people worldwide suffer from AKI every year, and about 1.7 million people die from AKI and its complications. AKI can occur in many clinical disciplines, especially in the ICU with an incidence...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4412A61P13/12
CPCA61K31/4412
Inventor 彭张哲孟婕李乾斌胡高云陶立坚
Owner CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com